US EditionINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ...
NEW YORK, UNITED STATES, JUN 27 – The lawsuit alleges Sarepta Therapeutics misled investors about ELEVIDYS safety, causing losses when undisclosed risks and severe side effects emerged, according to Rosen Law Firm.
- Levi & Korsinsky, LLP notified investors on July 24, 2025, of a class action lawsuit against Sarepta Therapeutics, Inc. listed on NASDAQ: SRPT.
- The lawsuit was initiated due to allegations that the defendants made false and misleading claims about the safety of the ELEVIDYS gene therapy during the period from mid-2023 to mid-2025.
- The complaint claims ELEVIDYS posed significant safety risks, failed to detect severe side effects, and caused Sarepta to halt trial recruitment, attracting regulatory scrutiny.
- Investors affected during the class period may seek lead plaintiff status by August 25, 2025, and compensation might be available without out-of-pocket costs.
- Levi & Korsinsky, ranked among the top securities litigation firms for seven consecutive years, and the Rosen Law Firm, known for major settlements, are involved in representing investors.
Insights by Ground AI
Does this summary seem wrong?
116 Articles
116 Articles
Coverage Details
Total News Sources116
Leaning Left17Leaning Right10Center35Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 27%
C 56%
R 16%
Factuality
To view factuality data please Upgrade to Premium
